Stem cells in cardiovascular diseases: turning bad days into good ones

Drug Discovery Today

Volumn 22, Issue 11, 2017, Pages 1730-1739

  Oliveira, Maira Souza de ^a   Saldanha Araujo, Felipe ^b   Goes, Alfredo Miranda de ^a   Costa, Fabricio F ^b,d,e   de Carvalho, Juliana Lott ^a,b,c,f  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b UNIVERSITY OF BRASILIA   (Brazil)

^c CellSeq Solutions   (Brazil)

^d MATTER   (United States)

^e The Founder Institute   (United States)

^f OneSkin Technologies   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOVASCULAR DISEASE; CELL POPULATION; CELLS BY BODY ANATOMY; CLINICAL TRIAL (TOPIC); HEART DISEASE; HUMAN; IN VITRO STUDY; MESENCHYMAL STEM CELL; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHYSIOLOGICAL PROCESS; PLURIPOTENT STEM CELL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SHORT COURSE THERAPY; SKELETAL MYOBLAST; STEM CELL; STEM CELL TRANSPLANTATION; ANIMAL; CYTOLOGY; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMA CELL; PATHOPHYSIOLOGY; PROCEDURES; TRANSPLANTATION;

ANIMALS; CARDIOVASCULAR DISEASES; HUMANS; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; PLURIPOTENT STEM CELLS;

EID: 85034094043     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2017.07.012     Document Type: Review

References (92)

1. Till, J.E., McCulloch, E.A., A direct measurement of the radiation sensitivity of normal mouse bone marrow cells. Radiat. Res. 14 (1961), 213–222.
2. Gordon, A.S., Haemopoietic Cells. Book review: Frontiers of Biology, (Vol. 24). Metcalf, D., Moore, M.A.S., (eds.) Science, 178, 1972, Elsevier, North-Holland, Amsterdam, New York, 974–975.
3. Friedenstein, A.J., et al. The development of fibroblast colonies in monolayer cultures of guinea-pig bone marrow and spleen cells. Cell Tissue Kinet. 3 (1970), 393–403.
4. Bianco, P., et al. Mesenchymal stem cells: revisiting history, concepts, and assays. Cell Stem Cell 2 (2008), 313–319.
5. Crisan, M., et al. A perivascular origin for mesenchymal stem cells in multiple human organs. Cell Stem Cell 3 (2008), 301–313.
6. Miranda, S.C.C.C., et al. Mesenchymal stem cells associated with porous chitosan-gelatin scaffold: a potential strategy for alveolar bone regeneration. J. Biomed. Mater. Res. A 100 (2012), 2775–2786.
7. Giarratana, M.-C., et al. Proof of principle for transfusion of in vitro-generated red blood cells. Blood 118 (2011), 5071–5079.
8. Wang, Y., et al. Liver-derived human mesenchymal stem cells: a novel therapeutic source for liver diseases. Stem Cell Res. Ther., 7, 2016, 71.
9. Patel, A.N., et al. Mesenchymal stem cell population isolated from the subepithelial layer of umbilical cord tissue. Cell Transplant 22 (2013), 513–519.
10. Hashmi, S., et al. Survival after mesenchymal stromal cell therapy in steroid-refractory acute graft-versus-host disease: systematic review and meta-analysis. Lancet Haematol. 3 (2016), e45–e52.
11. Evans, M.J., Kaufman, M.H., Establishment in culture of pluripotential cells from mouse embryos. Nature 292 (1981), 154–156.
12. Thomson, J.A., et al. Embryonic stem cell lines derived from human blastocysts. Science 282 (1998), 1145–1147.
13. Takahashi, K., Yamanaka, S., Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126 (2006), 663–676.
14. Takahashi, K., et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131 (2007), 861–872.
15. De Los Angeles, A., et al. Hallmarks of pluripotency. Nature 525 (2015), 469–478.
16. Wagers, A.J., Weissman, I.L., Plasticity of adult stem cells. Cell 116 (2004), 639–648.
17. Egashira, T., et al. Patient-specific induced pluripotent stem cell models: characterization of iPS cell-derived cardiomyocytes. Methods Mol. Biol. 1353 (2014), 343–353.
18. Trounson, A., DeWitt, N.D., Pluripotent stem cells progressing to the clinic. Nat. Rev. Mol. Cell Biol. 17 (2016), 194–200.
19. Golpanian, S., et al. Rebuilding the damaged heart: mesenchymal stem cells, cell-based therapy, and engineered heart tissue. Physiol. Rev. 96 (2016), 1127–1168.
20. Strauer, B.E., et al. Repair of infarcted myocardium by autologous intracoronary mononuclear bone marrow cell transplantation in humans. Circulation 106 (2002), 1913–1918.
21. Bartunek, J., et al. Cardiopoietic stem cell therapy in heart failure: the C-CURE (Cardiopoietic stem Cell therapy in heart failURE) multicenter randomized trial with lineage-specified biologics. J. Am. Coll. Cardiol. 61 (2013), 2329–2338.
22. Heldman, A.W., et al. Transendocardial mesenchymal stem cells and mononuclear bone marrow cells for ischemic cardiomyopathy: the TAC-HFT randomized trial. JAMA 311 (2014), 62–73.
23. Nowbar, A.N., et al. Discrepancies in autologous bone marrow stem cell trials and enhancement of ejection fraction (DAMASCENE): weighted regression and meta-analysis. BMJ, 348, 2014, g2688.
24. Gyöngyösi, M., et al. Meta-analysis of cell-based CaRdiac stUdiEs (ACCRUE) in patients with acute myocardial infarction based on individual patient data. Circ. Res. 116 (2015), 1346–1360.
25. Hare, J.M., et al. Comparison of allogeneic vs autologous bone marrow-derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trial. JAMA 308 (2012), 2369–2379.
26. Suncion, V.Y., et al. Does transendocardial injection of mesenchymal stem cells improve myocardial function locally or globally? An analysis from the Percutaneous Stem Cell Injection Delivery Effects on Neomyogenesis (POSEIDON) randomized trial. Circ. Res. 114 (2014), 1292–1301.
27. Lo Furno, D., et al. Potential therapeutic applications of adipose-derived mesenchymal stem cells. Stem Cells Dev. 25:21 (2016), 1615–1628, 10.1089/scd.2016.0135.
28. Fuchs, S., et al. Catheter-based autologous bone marrow myocardial injection in no-option patients with advanced coronary artery disease: a feasibility study. J. Am. Coll. Cardiol. 41 (2003), 1721–1724.
29. Trounson, A., McDonald, C., Stem cell therapies in clinical trials: progress and challenges. Cell Stem Cell 17 (2015), 11–22.
30. Nguyen, P.K., et al. Adult stem cell therapy and heart failure, 2000 to 2016: a systematic review. JAMA Cardiol. 1 (2016), 831–841.
31. Marks, P.W., et al. Clarifying stem-cell therapy's benefits and risks. N. Engl. J. Med. 376 (2017), 1007–1009.
32. Nakanishi, C., et al. Activation of cardiac progenitor cells through paracrine effects of mesenchymal stem cells. Biochem. Biophys. Res. Commun. 374 (2008), 11–16.
33. Hodgkinson, C.P., et al. Emerging concepts in paracrine mechanisms in regenerative cardiovascular medicine and biology. Circ. Res. 118 (2016), 95–107.
34. Syed, B.A., Evans, J.B., Stem cell therapy market. Nat. Rev. Drug Discov. 12 (2013), 185–186.
35. Fung, M., et al. Responsible translation of stem cell research: an assessment of clinical trial registration and publications. Stem Cell Rep. 8 (2017), 1190–1201.
36. Harrison, R.K., Phase II and Phase III failures: 2013–2015. Nat. Rev. Drug Discov. 15 (2016), 817–818.
37. Siegel, G., et al. Bone marrow-derived human mesenchymal stem cells express cardiomyogenic proteins but do not exhibit functional cardiomyogenic differentiation potential. Stem Cells Dev. 21 (2012), 2457–2470.
38. Li, L., et al. How to improve the survival of transplanted mesenchymal stem cell in ischemic heart?. Stem Cells Int., 2016, 2016, 9682757.
39. Yang, Y.-J., et al. Combined therapy with simvastatin and bone marrow-derived mesenchymal stem cells increases benefits in infarcted swine hearts. Arterioscler. Thromb. Vasc. Biol. 29 (2009), 2076–2082.
40. Assis, A.C.M., et al. Time-dependent migration of systemically delivered bone marrow mesenchymal stem cells to the infarcted heart. Cell Transplant 19 (2010), 219–230.
41. Toma, C., et al. Human mesenchymal stem cells differentiate to a cardiomyocyte phenotype in the adult murine heart. Circulation 105 (2002), 93–98.
42. Shim, W.S.N., et al. Ex vivo differentiation of human adult bone marrow stem cells into cardiomyocyte-like cells. Biochem. Biophys. Res. Commun. 324 (2004), 481–488.
43. Carvalho, J.L., et al. Priming mesenchymal stem cells boosts stem cell therapy to treat myocardial infarction. J. Cell Mol. Med. 17 (2013), 617–625.
44. Shinmura, D., et al. Pretreatment of human mesenchymal stem cells with pioglitazone improved efficiency of cardiomyogenic transdifferentiation and cardiac function. Stem Cells 29 (2011), 357–366.
45. Narita, T., et al. The use of scaffold-free cell sheet technique to refine mesenchymal stromal cell-based therapy for heart failure. Mol. Ther. 21 (2013), 860–867.
46. Kawamura, M., et al. Feasibility, safety, and therapeutic efficacy of human induced pluripotent stem cell-derived cardiomyocyte sheets in a porcine ischemic cardiomyopathy model. Circulation 126 (2012), S29–37.
47. Cartarozzi, L.P., et al. Mesenchymal stem cells engrafted in a fibrin scaffold stimulate Schwann cell reactivity and axonal regeneration following sciatic nerve tubulization. Brain Stem Cells Dev. 112 (2015), 14–24.
48. Mu, D., et al. Intracoronary transplantation of mesenchymal stem cells with overexpressed integrin-linked kinase improves cardiac function in porcine myocardial infarction. Sci. Rep., 6, 2016, 19155.
49. Menasché, P., et al. Human embryonic stem cell-derived cardiac progenitors for severe heart failure treatment: first clinical case report. Eur. Heart J. 36 (2015), 2011–2017.
50. Menasché, P., et al. Towards a clinical use of human embryonic stem cell-derived cardiac progenitors: a translational experience. Eur. Heart J. 36 (2015), 743–750.
51. Peterson, S.E., Loring, J.F.1, Genomic instability in pluripotent stem cells: implications for clinical applications. J. Biol. Chem. 289 (2014), 4578–4584.
52. Chong, J.J.H., et al. Human embryonic-stem-cell-derived cardiomyocytes regenerate non-human primate hearts. Nature 510 (2014), 273–277.
53. Templin, C., et al. Transplantation and tracking of human-induced pluripotent stem cells in a pig model of myocardial infarction: assessment of cell survival, engraftment, and distribution by hybrid single photon emission computed tomography/computed tomography of sodium iodide symporter transgene expression. Circulation 126 (2012), 430–439.
54. Ye, L., et al. Cardiac repair in a porcine model of acute myocardial infarction with human induced pluripotent stem cell-derived cardiovascular cells. Cell Stem Cell 15 (2014), 750–761.
55. Garber, K., RIKEN suspends first clinical trial involving induced pluripotent stem cells. Nat. Biotechnol. 33 (2015), 890–891.
56. Mandai, M., et al. Autologous induced stem-cell-derived retinal cells for macular degeneration. N. Engl. J. Med. 376 (2017), 1038–1046.
57. Devine, H., Patani, R., The translational potential of human induced pluripotent stem cells for clinical neurology. Cell Biol. Toxicol., 33, 2017, 129.
58. Todorova, D., et al. Brief Report: Immune microenvironment determines the immunogenicity of induced pluripotent stem cell derivatives. Stem Cells 34 (2016), 510–515.
59. Zhao, T., et al. Immunogenicity of induced pluripotent stem cells. Nature 474 (2011), 212–215.
60. Guha, P., et al. Lack of immune response to differentiated cells derived from syngeneic induced pluripotent stem cells. Cell Stem Cell 12 (2013), 407–412.
61. de Almeida, P.E., et al. Transplanted terminally differentiated induced pluripotent stem cells are accepted by immune mechanisms similar to self-tolerance. Nat. Commun., 5, 2014, 3903.
62. Liu, Z., et al. Molecular imaging of induced pluripotent stem cell immunogenicity with in vivo development in ischemic myocardium. PLoS One, 8, 2013, e66369.
63. Menasché, P., et al. The Myoblast Autologous Grafting in Ischemic Cardiomyopathy (MAGIC) Trial: first randomized placebo-controlled study of myoblast transplantation. Circulation 117 (2008), 1189–1200.
64. Zwetsloot, P.P., et al. Cardiac stem cell treatment in myocardial infarction: a systematic review and meta-analysis of preclinical studies. Circ. Res. 118 (2016), 1223–1232.
65. Itskovitz-Eldor, J., et al. Differentiation of human embryonic stem cells into embryoid bodies compromising the three embryonic germ layers. Mol. Med. 6 (2000), 88–95.
66. Kehat, I., et al. Human embryonic stem cells can differentiate into myocytes with structural and functional properties of cardiomyocytes. J. Clin. Invest. 108 (2001), 407–414.
67. Mummery, C., et al. Differentiation of human embryonic stem cells to cardiomyocytes: role of coculture with visceral endoderm-like cells. Circulation 107 (2003), 2733–2740.
68. Lian, X., et al. Robust cardiomyocyte differentiation from human pluripotent stem cells via temporal modulation of canonical Wnt signaling. Proc. Natl. Acad. Sci. U. S. A. 109 (2012), E1848–1857.
69. Pointon, A., et al. Assessment of cardiomyocyte contraction in human-induced pluripotent stem cell-derived cardiomyocytes. Toxicol. Sci. 144 (2015), 227–237.
70. Cook, D., et al. Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework. Nat. Rev. Drug Discov. 13 (2014), 419–431.
71. Raval, K.K., et al. Pompe disease results in a Golgi-based glycosylation deficit in human induced pluripotent stem cell-derived cardiomyocytes. J. Biol. Chem. 290 (2015), 3121–3136.
72. Kinnear, C., et al. Modeling and rescue of the vascular phenotype of Williams–Beuren syndrome in patient induced pluripotent stem cells. Stem Cells Transl. Med. 2 (2013), 2–15.
73. Drawnel, F.M., et al. Disease modeling and phenotypic drug screening for diabetic cardiomyopathy using human induced pluripotent stem cells. Cell Rep. 9 (2014), 810–821.
74. Sun, N., et al. Patient-specific induced pluripotent stem cells as a model for familial dilated cardiomyopathy. Sci. Transl. Med., 4, 2012, 130ra47.
75. Lan, F., et al. Abnormal calcium handling properties underlie familial hypertrophic cardiomyopathy pathology in patient-specific induced pluripotent stem cells. Cell Stem Cell 12 (2013), 101–113.
76. Kim, C., et al. Studying arrhythmogenic right ventricular dysplasia with patient-specific iPSCs. Nature 494 (2013), 105–110.
77. Aggarwal, P., et al. RNA expression profiling of human iPSC-derived cardiomyocytes in a cardiac hypertrophy model. PLoS One, 9, 2014, e108051.
78. Belair, D.G., et al. Human vascular tissue models formed from human induced pluripotent stem cell derived endothelial cells. Stem Cell Rev. 11 (2015), 511–525.
79. Dash, B.C., et al. Induced pluripotent stem cell-derived vascular smooth muscle cells: methods and application. Biochem. J. 465 (2015), 185–194.
80. Scott, C.W., et al. An impedance-based cellular assay using human iPSC-derived cardiomyocytes to quantify modulators of cardiac contractility. Toxicol. Sci. 142 (2014), 331–338.
81. Inoue, H., et al. iPS cells: a game changer for future medicine. EMBO J. 33 (2014), 409–417.
82. Asai, M., et al. Modeling Alzheimer's disease using iPS cells reveals stress phenotypes associated with intracellular beta-amyloid oligomer and differential drug responsiveness. Alzheimers Dement., 9, 2013, P185.
83. Israel, M.A., et al. Probing sporadic and familial Alzheimer's disease using induced pluripotent stem cells. Nature 482 (2012), 216–220.
84. Jin, Z.-B., et al. Modeling retinal degeneration using patient-specific induced pluripotent stem cells. PLoS One, 6, 2011, e17084.
85. Garbes, L., et al. VPA response in SMA is suppressed by the fatty acid translocase CD36. Hum. Mol. Genet. 22 (2013), 398–407.
86. Penttinen, K., et al. Antiarrhythmic effects of dantrolene in patients with catecholaminergic polymorphic ventricular tachycardia and replication of the responses using iPSC models. PLoS One, 10, 2015, e0125366.
87. Quyyumi, A.A., et al. PreSERVE-AMI: a randomized, double-blind, placebo-controlled clinical trial of intracoronary administration of autologous C+ cells in patients with left ventricular dysfunction post STEMI. Circ. Res. 120 (2017), 324–331, 10.1161/CIRCRESAHA.115.308165.
88. Houtgraaf, J.H., et al. First experience in humans using adipose tissue-derived regenerative cells in the treatment of patients with ST-segment elevation myocardial infarction. J. Am. Coll. Cardiol. 59 (2012), 539–540.
89. Rolf, A., et al. Maladaptive hypertrophy after acute myocardial infarction positive effect of bone marrow-derived stem cell therapy on regional remodeling measured by cardiac MRI. Clin. Res. Cardiol. 100 (2011), 983–992.
90. Hare, J.M., et al. A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction. J. Am. Coll. Cardiol. 54 (2009), 2277–2286.
91. Nasseri, B.A., et al. Autologous CD133+ bone marrow cells and bypass grafting for regeneration of ischaemic myocardium: the Cardio133 trial. Eur. Heart J. 35 (2014), 1263–1274.
92. Chullikana, A., et al. Randomized, double-blind, phase I/II study of intravenous allogeneic mesenchymal stromal cells in acute myocardial infarction. Cytotherapy 17 (2015), 250–261.